Abstract

Background and AimsImmunoregulatory checkpoint receptors (CR) contribute to the profound immunoparesis observed in alcohol-related liver disease (ALD) and in vitro neutralization of inhibitory-CRs TIM3/PD1 on anti-bacterial T-cells can rescue innate and adaptive anti-bacterial immunity. Recently described soluble-CR forms can modulate immunity in inflammatory conditions, but the contributions of soluble-TIM3 and soluble-PD1 and other soluble-CRs to immune derangements in ALD remain unclear.MethodsIn Alcoholic Hepatitis (AH; n = 19), alcohol-related cirrhosis (ARC; n = 53) and healthy control (HC; n = 27) subjects, we measured by Luminex technology (i) plasma levels of 16 soluble-CRs, 12 pro/anti-inflammatory cytokines and markers of gut bacterial translocation; (ii) pre-hepatic, post-hepatic and non-hepatic soluble-CR plasma levels in ARC patients undergoing TIPS; (iii) soluble-CRs production from ethanol-treated immunocompetent precision cut human liver slices (PCLS); (iv) whole-blood soluble-CR expression upon bacterial challenge. By FACS, we assessed the relationship between soluble-TIM3 and membrane-TIM3 and rescue of immunity in bacterial-challenged PBMCs.ResultsSoluble-TIM3 was the dominant plasma soluble-CR in ALD vs. HC (p = 0.00002) and multivariate analysis identified it as the main driver of differences between groups. Soluble-CRs were strongly correlated with pro-inflammatory cytokines, gut bacterial translocation markers and clinical indices of disease severity. Ethanol exposure or bacterial challenge did not induce soluble-TIM3 production from PCLS nor from whole-blood. Bacterial challenge prompted membrane-TIM3 hyperexpression on PBMCs from ALD patient’s vs. HC (p < 0.002) and was inversely correlated with plasma soluble-TIM3 levels in matched patients. TIM3 ligands soluble-Galectin-9 and soluble-CEACAM1 were elevated in ALD plasma (AH > ARC; p < 0.002). In vitro neutralization of Galectin-9 and soluble-CEACAM1 improved the defective anti-bacterial and anti-inflammatory cytokine production from E. coli-challenged PBMCs in ALD patients.ConclusionsAlcohol-related liver disease patients exhibit supra-physiological plasma levels of soluble-TIM3, particularly those with greater disease severity. This is also associated with increased levels of soluble TIM3-ligands and membrane-TIM3 expression on immune cells. Soluble-TIM3 can block the TIM3-ligand synapse and improve anti-bacterial immunity; however, the increased levels of soluble TIM3-binding ligands in patients with ALD negate any potential immunostimulatory effects. We believe that anti-TIM3 neutralizing antibodies currently in Phase I clinical trials or soluble-TIM3 should be investigated further for their ability to enhance anti-bacterial immunity. These agents could potentially represent an innovative immune-based supportive approach to rescue anti-bacterial defenses in ALD patients.

Highlights

  • Alcohol-related liver disease (ALD) represents a significant public health burden, and according to the World Health Organization alcohol is “the third highest risk factor for premature mortality, disability and loss of health worldwide” (Soria Saucedo, 2013)

  • Systemic levels of soluble-T-cell immunoglobulin and mucin domain 3 (TIM3) were highly elevated in ALD patients and the most significantly different between groups amongst all the soluble-checkpoint receptors (CR) (Supplementary Table 2 and Figures 1A,B)

  • Compared to healthy controls (HC), solubleLAG3 was greater in patients (ALD > HC), while solubleHVEM was lower in patients (ALD < HC); differences for soluble-lymphocyte-activation gene 3 (LAG3) and soluble-herpesvirus entry mediator (HVEM) between groups were only borderline significant (Figures 1A,D)

Read more

Summary

Introduction

Alcohol-related liver disease (ALD) represents a significant public health burden, and according to the World Health Organization alcohol is “the third highest risk factor for premature mortality, disability and loss of health worldwide” (Soria Saucedo, 2013). Therapeutics have primarily focussed on (i) curtailing the infection with use of widespread antibiotics, concerningly this has promoted development of multi-drug resistant microbes (Merli et al, 2015; Fernandez et al, 2016; EASL, 2018), or (ii) bridling the rampant inflammation with immunosuppressive agents This latter strategy can potentiate the immunocompromised state and increase the risk of secondary infections (Louvet et al, 2009; Thursz et al, 2015; Vergis et al, 2017; Chokshi, 2018). Described soluble-CR forms can modulate immunity in inflammatory conditions, but the contributions of soluble-TIM3 and solublePD1 and other soluble-CRs to immune derangements in ALD remain unclear

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call